string(10) "User ID: 0" Symbiotics Emerging Credit Fund • Symbiotics Asset Management

Symbiotics Asset Management

This site is intended for professional and institutional investors only. Please confirm your location and investor profile so that we can direct you to the most appropriate content.

Back to Home   Accept and Continue

DISCLAIMER

Any information provided herein is exclusively, for the Swiss market, for the attention of qualified investors as per the Swiss Collective Investment Scheme Act (“CISA”) and the Ordinance on Collective Investment Schemes in Switzerland (“CISO”), as amended from time to time.

Qualified investors pursuant to Art. 10 para. 3 and Art. 10 para. 3ter CISA are:
  • 1. financial intermediaries as defined in the Swiss Banking Act of 8 November 1934, the Swiss Financial Institutions Act of 15 June 2018 (“FinIA”) and CISA;
  • 2. supervised insurance institutions;
  • 3. foreign entities subject to prudential supervision as the persons listed in 1. and 2.;
  • 4. central banks;
  • 5. public entities with professional treasury operations;
  • 6. occupational pension schemes with professional treasury operations and other occupational pension institutions providing professional treasury operations,
  • 7. companies with professional treasury operations;
  • 8. large companies; a “large company” is defined as a company which exceeds two of the following parameters: balance sheet total of CHF 20 million, turnover of CHF 40 million or equity of CHF 2 million.
  • 9. private investment structures with professional treasury operations created for high-net-worth retail clients;
  • 10. High-net-worth individuals who declare in writing that they wish to be deemed qualified investors; a “high-net-worth individual” in the sense of the preceding sentence is any natural person who at the time of subscribing to the collective investment scheme meets one of the following conditions: (i) natural persons who demonstrate that either (i) on the basis of training, education and professional experience or on the basis of comparable experience in the financial sector, they possess the necessary knowledge to understand the risks associated with the investments and have at their disposal assets of at least CHF 500’000; or (ii) have at their disposal assets of at least CHF 2 million.

Furthermore, investors for whom a financial intermediary in accordance with Art. 4 par. 3 letter a Financial Services Act (“FinSA”) or a foreign financial intermediary that is subject to equivalent prudential supervision provides portfolio management or investment advice in accordance with Art. 3 letter c items 3 and 4 FinSA within the scope of a permanent portfolio management or investment advice relationship are deemed qualified investors unless they have declared in writing that they do not wish to be treated as such. Such declaration must be made in writing or in another form demonstrable via text.

By clicking "AGREE", you confirm to be a qualified investor pursuant to Art.10 para. 3 and Art.10 para. 3ter CISA.

Disagree   Agree

This material was produced by Symbiotics Asset Management SA (“the Company”), a Swiss regulated entity by the FINMA, for information only and must not be distributed, published, reproduced or disclosed by recipients to any other person. All information contained in this document is subject to change at any time without notice. Symbiotics Asset Management SA provides no guarantee with regard to the accuracy and completeness of the content in this publication and the Company does not under any circumstance, accept liability for any direct or indirect loss or damages which may arise from making use of, or relying upon any information, content or opinion in this publication. The information disclosed herein is the sole property of the Company unless otherwise noted, and may not be reproduced in full or in part without the express prior written consent of Symbiotics Asset Management SA.

This is a marketing communication. Please refer to the prospectus (available in English) before making any final investment decisions. All investments involve risk. Past performance is not an indication of future results. Emerging markets impact investments involve a unique and substantial level of risk that is critical to understand before engaging in any prospective relationship with the Company and its various managed funds. Investments in emerging markets, particularly those involving foreign currencies, may present significant additional risk and in all cases the risks implicated in this disclaimer include the risk of loss of invested capital.

Symbiotics Asset Management SA disclaims all liability for any direct or indirect damages and/or costs that may arise from the use of (whether such use is proper or improper), or access to, this publication.

© Copyright Symbiotics Asset Management SA 2026. All rights reserved.

Disagree  

Any information provided herein is exclusively for the attention of professional investors, or similar notion corresponding to the classification of the Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU revised Markets in Financial Directives (MiFID II). By clicking “AGREE” you confirm to be a pprofessional investor in the sense of Annex II to MiFID II.

For your information, Professional client pursuant to Annex II to MiFID II means is a client who possesses the experience, knowledge, and expertise to make its own investment decisions and properly assess the risks that it incurs.

Professional client must comply with the following criteria.

I. Categories of client who are considered to be professionals :
  • (1) Entities that are required to be authorized or regulated to operate in the financial markets. The list below shall be understood as including all authorized entities carrying out the characteristic activities of the entities mentioned: entities authorized by a Member State under a Directive, entities authorized or regulated by a Member State without reference to a Directive, and entities authorized or regulated by a third country:
    1. (a) Credit institutions;
    2. (b) Investment firms;
    3. (c) Other authorized or regulated financial institutions;
    4. (d) Insurance companies;
    5. (e) Collective investment schemes and management companies of such schemes;
    6. (f) Pension funds and management companies of such funds;
    7. (g) Commodity and commodity derivatives dealers;
    8. (h) Locals;
    9. (i) Other institutional investors;
  • (2) Large undertakings meeting two of the following size requirements on a company basis:- balance sheet total: EUR 20,000,000, - net turnover: EUR 40,000,000, - own funds: EUR 2,000,000.
  • (3) National and regional governments, including public bodies that manage public debt at national or regional level, Central Banks, international and supranational institutions such as the World Bank, the IMF, the ECB, the EIB and other similar international organizations.
  • (4) Other institutional investors whose main activity is to invest in financial instruments, including entities dedicated to the securitization of assets or other financing transactions
II. Clients who may be treated as professionals on request.

Clients other than those mentioned in section I, including public sector bodies, local public authorities, municipalities, and private individual investors, may also be allowed to waive some of the protections afforded by the conduct of business rules.

The regulation governing the marketing of financial instruments varies from country to country and from your specific status. If you have any doubts, we invite you to contact your advisor. No investment funds may be offered to a potential investor if the regulation pertaining to him or to the product prohibits such offering.

Disagree   Agree

This material was produced by Symbiotics France SA (“the Company”), qualified as a gestionnaire de fonds d’investissement alternatifs under the AIFM Directive and supervised by the French Autorité des Marchés Financiers, under the number GP-20000018, for information only and must not be distributed, published, reproduced or disclosed by recipients to any other person. All information contained in this document is subject to change at any time without notice. Symbiotics France SA provides no guarantee with regard to the accuracy and completeness of the content in this publication and the Company does not under any circumstance, accept liability for any direct or indirect loss or damages which may arise from making use of, or relying upon any information, content or opinion in this publication. The information disclosed herein is the sole property of the Company unless otherwise noted, and may not be reproduced in full or in part without the express prior written consent of Symbiotics France SA.

This is a marketing communication. Please refer to the prospectus (available in English) before making any final investment decisions. All investments involve risk. Past performance is not an indication of future results. Emerging markets impact investments involve a unique and substantial level of risk that is critical to understand before engaging in any prospective relationship with the Company and its various managed funds. Investments in emerging markets, particularly those involving foreign currencies, may present significant additional risk and in all cases the risks implicated in this disclaimer include the risk of loss of invested capital.

Symbiotics France SA disclaims all liability for any direct or indirect damages and/or costs that may arise from the use of (whether such use is proper or improper), or access to, this publication.

© Copyright Symbiotics France SA 2026. All rights reserved.

Disagree  

Any information provided herein is exclusively for the attention of professional investors, in the sense of the Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU revised Markets in Financial Directives (MiFID II). By clicking “AGREE” you confirm to be a professional investor in the sense of Annex II to MiFID II.

For your information, Professional client pursuant to Annex II to MiFID II means is a client who possesses the experience, knowledge, and expertise to make its own investment decisions and properly assess the risks that it incurs.

Professional client must comply with the following criteria.

I. Categories of client who are considered to be professionals :
  • (1) Entities which are required to be authorized or regulated to operate in the financial markets. The list below shall be understood as including all authorized entities carrying out the characteristic activities of the entities mentioned: entities authorized by a Member State under a Directive, entities authorized or regulated by a Member State without reference to a Directive, and entities authorized or regulated by a third country:
    1. (a) Credit institutions;
    2. (b) Investment firms;
    3. (c) Other authorized or regulated financial institutions;
    4. (d) Insurance companies;
    5. (e) Collective investment schemes and management companies of such schemes;
    6. (f) Pension funds and management companies of such funds;
    7. (g) Commodity and commodity derivatives dealers;
    8. (h) Locals;
    9. (i) Other institutional investors;
  • (2) Large undertakings meeting two of the following size requirements on a company basis:- balance sheet total: EUR 20’000’000, - net turnover : EUR 40’000’000, - own funds: EUR 2’000’000.
  • (3) National and regional governments, including public bodies that manage public debt at national or regional level, Central Banks, international and supranational institutions such as the World Bank, the IMF, the ECB, the EIB and other similar international organizations.
  • (4) Other institutional investors whose main activity is to invest in financial instruments, including entities dedicated to the securitization of assets or other financing transactions.
II. Clients who may be treated as professionals on request.

Clients other than those mentioned in section I, including public sector bodies, local public authorities, municipalities, and private individual investors, may also be allowed to waive some of the protections afforded by the conduct of business rules.

The regulation governing the marketing of financial instruments varies from country to country and from your specific status. If you have any doubts, we invite you to contact your advisor. No investment funds may be offered to a potential investor if the regulation pertaining to him or to the product prohibits such offering.

Disagree   Agree

This material was produced by Symbiotics France SA (“the Company”), qualified as a gestionnaire de fonds d’investissement alternatifs under the AIFM Directive and supervised by the French Autorité des Marchés Financiers, under the number GP-20000018, for information only and must not be distributed, published, reproduced or disclosed by recipients to any other person. All information contained in this document is subject to change at any time without notice. Symbiotics France SA provides no guarantee with regard to the accuracy and completeness of the content in this publication and the Company does not under any circumstance, accept liability for any direct or indirect loss or damages which may arise from making use of, or relying upon any information, content or opinion in this publication. The information disclosed herein is the sole property of the Company unless otherwise noted, and may not be reproduced in full or in part without the express prior written consent of Symbiotics France SA.

This is a marketing communication. Please refer to the prospectus (available in English) before making any final investment decisions. All investments involve risk. Past performance is not an indication of future results. Emerging markets impact investments involve a unique and substantial level of risk that is critical to understand before engaging in any prospective relationship with the Company and its various managed funds. Investments in emerging markets, particularly those involving foreign currencies, may present significant additional risk and in all cases the risks implicated in this disclaimer include the risk of loss of invested capital.

Symbiotics France SA disclaims all liability for any direct or indirect damages and/or costs that may arise from the use of (whether such use is proper or improper), or access to, this publication.

© Copyright Symbiotics France SA 2026. All rights reserved..

Disagree